UK decision to sell statins over the counter criticized

Meek, Colin
June 2005
CMAJ: Canadian Medical Association Journal;6/7/2005, Vol. 172 Issue 12, p1543
Academic Journal
Reports on criticisms regarding the decision of the British drug regulatory agency to sell over-the-counter (OTC) statins on the basis of inconclusive evidence. Reason behind the decision of the agency; Background on simvastatin; Concerns of the "Drug and Therapy Bulletin" on the OTC protocol used to assess risk.


Related Articles

  • OTC statins: a step too far? Minhas, Rubin // GP: General Practitioner;6/16/2003, p41 

    The prospect of patients buying their own statins may be closer to becoming reality following calls by clinicians, including some from the ASCOT study group, for these drugs to be made available OTC. Recent trial data have given fresh impetus to calls to lower risk thresholds for CHD primary...

  • New CHD guidelines to pave way for OTC statins. Polak, Monika // GP: General Practitioner;5/12/2003, p20 

    This article reports that the benefits of statins may lead to their wider availability. The government of Great Britain has signaled it would welcome manufacturers applying for Over-The-Counter licenses. However, even before the government's enthusiasm for statins, the Joint British Societies...

  • Consumer understanding in question, statin switch is dead. Johnsen, Mihcael // Drug Store News;2/14/2005, Vol. 27 Issue 2, p20 

    Reports on the expectation of the decision of the U.S. Food and Drug Administration for the over-the-counter availability of statins in the U.S. Distribution system of drugs; Accessibility of statins; Opportunity of customers to choose the right drugs.

  • Statin scripts fall.  // Pulse;3/23/2006, Vol. 66 Issue 12, p22 

    The article reports on the decline in general practitioners' prescription of statins in Great Britain. A research, led by Kris Filion, linked the decline to simvastatin becoming available over the counter in 2004. Since 2001, prescriptions for the drug had been increasing by 14,900 per quarter....

  • Move to sell statins over the counter raises concerns. Gibson, Liza // BMJ: British Medical Journal (International Edition);5/22/2004, Vol. 328 Issue 7450, p1221 

    Focuses on the concerns raised by doctors' leaders and consumer bodies about the United Kingdom government's decision to allow the cholesterol lowering agent, simvastatin, to become available without prescription in pharmacies. Cost of the drug for the NHS; Need for the pharmacy to undertake a...

  • From the analyst's couch: Statin switch to OTC. Link, Martyn // Nature Reviews Drug Discovery;Aug2004, Vol. 3 Issue 8, p641 

    Focuses on the approval of the first over-the-counter (OTC) statin drug in Great Britain. Impact of switching medicines from prescription-only drugs to OTC status; Benefit of OTC drugs for the government and the general practitioners; Consistency of the British government's move of OTC switching...

  • Statins and Over-the-Counter Availability. Strom, Brian L. // New England Journal of Medicine;4/7/2005, Vol. 352 Issue 14, p1403 

    Focuses on statins and how a proposal for them to be sold over-the-counter without a prescription was rejected. Advantages of being able to buy drugs without a prescription; Potential disadvantages; How drugs are eligible for over-the-counter status; Reasons that statins were rejected for such...

  • OTC Statins in the US?  // Pharmaceutical Executive;Sep2004, Vol. 24 Issue 9, p28 

    Presents a survey of the attitude of physicians abnd consumers on over-the-counter (OTC) statin drugs conducted by the National Lipid Association in the U.S. Importance for the U.S. Food and Drug Administration to evaluate the OTC statins; Approval of OTC statins for use in the country; Benefits...

  • Merck & Co: OTC Mevacor remains remote prospect.  // PharmaWatch: Monthly Review;Mar2005, Vol. 4 Issue 3, p13 

    The article reports on the recommendation issued by the U.S. Food and Drug Administration advisory committee to disapprove the over-the-counter Mevacor, a statin simvastatin. The committee rejected the proposal on the basis of two main concerns such as consumer understanding and inadequate...

  • Move to put low dose statins in pharmacy. Topham-Kindley, Liane // New Zealand Doctor;5/19/2004, p3 

    Reports that the Medicines Classification Committee of New Zealand will consider an application from HeartCare Plus to reclassify simvastatin from prescription drug to pharmacy-only medicine. Claims of HeartCare Plus in line with its application for the reclassification of simvastatin; Support...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics